All In Biotech

NDA 012911 · Esteve

Metopirone

Metyrapone · Oral · Adrenal Steroid Synthesis Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jul 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1961

Dec 4, 1961

Approved uses

1

Original approval plus efficacy supplements

Registered trials

24

3 Phase 3, 4 recruiting

FAERS reports

999

675 serious, 125 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 19, 2026.

Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. ( 1 )

Mechanism: The pharmacological effect of Metopirone is to reduce cortisol and corticosterone production by inhibiting the 11-beta-hydroxylation reaction in the adrenal cortex. Removal of the strong inhibitory feedback mechanism exerted by cortisol results in an increase in adrenocorticotropic hormone (ACTH) production by the pituitary. With continued blockade of the enzymatic steps leading to production of cortisol and corticosterone, there is a marked increase in adrenocortical secretion of their immediate precursors, 11-desoxycortisol and desoxycorticosterone, which are weak suppressors of ACTH...

Therapeutic areas: Kidney and urology · Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 4, 1961 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • METOPIRONE · METYRAPONE 250MG · CAPSULE, ORAL · Prescription
  • METOPIRONE · METYRAPONE 250MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Metyrapone" as an intervention, any sponsor and status, largest first.

All 24 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use383
  • nausea81
  • drug ineffective66
  • fatigue53
  • vomiting53
  • adrenal insufficiency45
  • asthenia41
  • dizziness41
  • death38
  • maternal exposure during pregnancy35
  • pneumocystis jirovecii pneumonia35
  • diarrhoea33

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20053
20069
200711
20083
200910
201013
201116
201226
201329
201411
201515
201617
201734
201882
201931
202057
202179
202283
202380
2024138
2025132
2026114

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Metopirone (Metyrapone)

2024 spending

$1.4M

Beneficiaries

42

132 claims

Per beneficiary

$32,176

$50.61 per unit

View as table
YearSpending
2020$524,745
2021$866,737
2022$1,085,332
2023$1,090,494
2024$1,351,407

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 137 on PubMed

Sponsor: Esteve

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.